drugset
drugset / Trial / NCT04896632

Study of Safety, Tolerability, and Pharmacokinetics of INE963 in Healthy Participants

NCT04896632 ↗

Phase 1 Terminated 64 enrolled Novartis Pharmaceuticals
RandomizedSequentialDouble-blindTreatment

Summary

The purpose of this study is to assess the safety, tolerability, and pharmacokinetics of single ascending doses and multiple doses of INE963 given orally in healthy participants.

Timeline

Start
2021-05-13
Primary completion
2022-11-24
Completion
2022-11-24

Drugs

EvaluationDrugModalityDoseRoute
Subject INE963 Small molecule — Oral

Indications

No indication recorded.